AlphaCentric Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

AlphaCentric Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.2M	Buy	4,931 +268	+6%	+$125K	2.2%	5
2025 Q4	$2.11M	Buy	+4,663	New	+$2.01M	2.11%	5
2024 Q4	$1.25M	Buy	+3,101	New	+$1.44M	1.25%	21
2021 Q4	–	Sell	-10,250	Closed	-$1.86M	–	276
2021 Q3	$1.86M	Buy	10,250 +3,000	+41%	+$586K	0.47%	8
2021 Q2	$1.46M	Buy	7,250 +3,250	+81%	+$680K	0.4%	12
2021 Q1	$860K	Buy	4,000 +2,950	+281%	+$648K	0.29%	26
2020 Q4	$248K	Buy	1,050 +1,040	+10,400%	+$239K	0.1%	54
2020 Q3	$3K	Hold	10	–	–	﹤0.01%	163
2020 Q2	$3K	Buy	+10	New	+$2.71K	﹤0.01%	144

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AlphaCentric Advisors's VRTX Position: Q1 2026 in Review

AlphaCentric Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 5.7% in Q1 2026, buying an estimated $125K and bringing the position to 4,931 shares worth $2.2M. The position accounts for 2.2% of the portfolio, ranked #5.

AlphaCentric Advisors first reported a position in VRTX in Q2 2020 and has held it in 9 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

AlphaCentric Advisors held 4,931 shares of Vertex Pharmaceuticals worth $2.2M as of Q1 2026.
AlphaCentric Advisors bought 268 Vertex Pharmaceuticals shares in Q1 2026, an estimated $125K.
Vertex Pharmaceuticals made up 2.2% of AlphaCentric Advisors's portfolio in Q1 2026, its #5 holding.
AlphaCentric Advisors first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 9 quarters since.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.